At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 437 enrolled
Drug / intervention
biphasic insulin aspart 30drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-week, Multinational, Multicentre, Randomised, Open Label, Parallel-group Treat-to-target Trial to Compare Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
In Brief
A Phase 4 clinical trial evaluating biphasic insulin aspart 30 for Diabetes and Type 2 Diabetes Mellitus. Completed, enrolled 437 participants across 50 sites in 7 countries.
Detailed Summary
This trial is conducted in Asia. The aim of the trial is to compare efficacy and safety of thrice daily versus twice daily NovoMix® 30 (Biphasic insulin aspart 30) in subjects with type 2 diabetes inadequately controlled with basal insulin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Type 2 Diabetes Mellitus
CountriesAlgeria, China, Hong Kong, India, Taiwan, Turkey (Türkiye), Ukraine
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartOct 2015
First PostedOct 2015
Primary CompletionMar 2017
Study CompletionApr 2017
TodayJul 2026
First PostedOct 21, 2015
Enrollment StartOct 19, 2015
Primary CompletionMar 18, 2017
Study CompletionApr 18, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.7 years ago
Interventions
biphasic insulin aspart 30drug
Administered subcutaneously (s.c., under the skin) thrice daily or twice daily. Subjects will continue with metformin all throughout the trial.